I’m back with another semi-regular column tracking the ups and downs in small-cap biotech. Today, I take a look at Fennec Pharma (FENC) and Actinium Pharma (ATNM). As a reminder, I’m taking requests for companies to cover, so reach out to me on Twitter (DMs are open), email, or in the comment section of the column.
Dr. Andrew Hong, a pediatric oncologist and instructor at Harvard Medical School, has mixed feelings about cisplatin, a commonly used platinum-based chemotherapy. The drug is highly effective, even curative, for children diagnosed with a variety of solid tumors. But cisplatin is also extremely toxic to the inner ear, so many of Hong’s young patients end up with profound and permanent hearing loss.